Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Neurocrine Biosciences reported very strong first-quarter 2026 results, with total revenues of $814.5 million, up 42% from the prior year, driven by growth in key neurology and endocrine drugs.
Net product sales reached $811.0 million, a 44% increase year-over-year. INGREZZA delivered $656.9 million in sales, up 20%, while newly launched CRENESSITY generated $153.3 million. GAAP net income jumped to $197.9 million, with diluted EPS of $1.91, and Non-GAAP EPS was $1.94.
The company entered a definitive agreement to acquire Soleno Therapeutics for an equity value of $2.9 billion, adding VYKAT XR for hyperphagia in Prader-Willi syndrome, and reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion. Cash, cash equivalents, and marketable securities totaled about $2.65 billion as of March 31, 2026.
Positive
- Revenue and earnings inflection: Q1 2026 revenues rose to $814.5 million (up 42% year-over-year), while GAAP diluted EPS jumped to $1.91 and Non-GAAP diluted EPS to $1.94, indicating a major step-up in profitability alongside strong top-line growth.
Negative
- None.
Insights
Neurocrine posts >40% revenue growth, major profit step-up, and a $2.9B rare-disease deal.
Neurocrine Biosciences delivered first-quarter 2026 revenues of $814.5 million, up 42% year-over-year, with net product sales of $811.0 million growing 44%. Growth was led by INGREZZA at $656.9 million and rapid CRENESSITY ramp to $153.3 million.
Profitability inflected sharply: GAAP net income rose to $197.9 million and diluted EPS to $1.91, while Non-GAAP EPS reached $1.94. Operating leverage came despite higher R&D and SG&A to support late-stage programs and commercial expansion, helped by milestones, equity investment gains, and a gain on a business sale.
Strategically, the $2.9 billion definitive agreement to acquire Soleno Therapeutics adds VYKAT XR for hyperphagia in Prader-Willi syndrome and deepens the rare-disease footprint. Management reaffirmed 2026 INGREZZA net sales guidance of $2.7–$2.8 billion, signaling confidence in demand trends. With about $2.65 billion in cash, cash equivalents, and marketable securities at March 31, 2026, the balance sheet provides substantial capacity to fund the pipeline and the pending acquisition.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenues: $814.5 million
Net product sales: $811.0 million
INGREZZA net product sales: $656.9 million
+5 more
8 metrics
Total revenues
$814.5 million
Three months ended March 31, 2026; vs $572.6 million in 2025 (42% increase)
Net product sales
$811.0 million
Q1 2026; 44% year-over-year growth
INGREZZA net product sales
$656.9 million
Q1 2026; 20% year-over-year growth
CRENESSITY net product sales
$153.3 million
Q1 2026; strong demand with ~80% reimbursement
GAAP diluted EPS
$1.91
Q1 2026; up from $0.08 in Q1 2025
Non-GAAP diluted EPS
$1.94
Three months ended March 31, 2026; vs $0.70 in 2025
Cash and marketable securities
$2.65 billion
Cash, cash equivalents, and marketable securities at March 31, 2026
Soleno acquisition equity value
$2.9 billion
Definitive agreement at $53.00 per share in cash
Key Terms
Non-GAAP, acquired in-process research and development, tardive dyskinesia, Prader-Willi syndrome, +2 more
6 terms
Non-GAAP financial
"this press release also contains the following Non-GAAP financial measures: Non-GAAP R&D expense"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
acquired in-process research and development financial
"Increased acquired in-process research and development (IPR&D) expense associated with upfront payments"
tardive dyskinesia medical
"treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia"
A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.
Prader-Willi syndrome medical
"VYKAT XR (diazoxide choline), a first-in-class therapy to treat hyperphagia in Prader-Willi syndrome (PWS)"
A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.
dual M1/M4 selective agonist medical
"Phase 2 clinical study of NBI-1117570, a dual M1/M4 selective agonist in adults with schizophrenia"
hyperphagia medical
"diazoxide choline), a first-in-class therapy to treat hyperphagia in Prader-Willi syndrome"
An abnormally strong, persistent urge to eat that leads to excessive food intake beyond normal hunger; it can be a symptom of neurological, hormonal, genetic, or psychiatric conditions. Investors care because therapies that reduce hyperphagia can become measurable drug trial endpoints, define patient populations and market size, and influence regulatory approval, reimbursement prospects and commercial potential in the obesity and rare-disease sectors.
Earnings Snapshot
Total revenues: $814.5 million · Guidance included
Q1 2026
Total revenues
$814.5 million
+42% YoY
Net product sales
$811.0 million
+44% YoY
INGREZZA net product sales
$656.9 million
+20% YoY
GAAP diluted EPS
$1.91
up from $0.08 in Q1 2025
Non-GAAP diluted EPS
$1.94
up from $0.70 in Q1 2025
Guidance
2026 INGREZZA net product sales guidance reaffirmed at $2.7–$2.8 billion; includes R&D and SG&A expense ranges reflecting continued portfolio and commercial investment.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
(Address of principal executive offices)
(Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 5, 2026, Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
| Exhibit | Description | |||||||
| 99.1 | Press Release dated May 5, 2026 | |||||||
| 104 | Cover Page Interactive Data File | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEUROCRINE BIOSCIENCES, INC. | |||||
Dated: May 5, 2026 | /s/ Matthew C. Abernethy | ||||
| Matthew C. Abernethy | |||||
| Chief Financial Officer (Duly authorized officer and Principle Financial Officer) | |||||
Exhibit 99.1
Neurocrine Biosciences Reports First-Quarter 2026
Financial Results
Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million,
An Increase of 44% Year-Over-Year
An Increase of 44% Year-Over-Year
Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026
Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia
Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion
SAN DIEGO, May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.
“Neurocrine’s strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY® (crinecerfont). Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth. With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth.”
Net Product Sales Highlights
•Total first-quarter 2026 net product sales were $811.0 million, representing 44% growth year-over-year.
•INGREZZA first-quarter 2026 net product sales were $656.9 million, representing 20% growth year-over-year. Results reflected double-digit prescription volume growth in TRx and record NRx driven by strong patient demand, partially offset by a lower net price compared to the first quarter of 2025.
•CRENESSITY first-quarter 2026 net product sales were $153.3 million, driven by strong patient demand with approximately 80% reimbursement for dispensed prescriptions in the first quarter 2026.
•Total revenues for the first quarter of 2026 were $814.5 million, compared with $572.6 million in the prior-year period, a 42% increase.
Recent Clinical and Corporate Developments
•Entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. The addition of VYKAT™ XR (diazoxide choline), a first-in-class therapy to treat hyperphagia in Prader-Willi syndrome (PWS), is expected to expand Neurocrine's portfolio of innovative medicines and strengthen its leadership position in endocrinology and rare disease. The acquisition is anticipated to close in the second quarter of 2026.
•Initiated and dosed the first patients in a Phase 2 clinical study of NBI-1117570, a dual M1/M4 selective agonist in adults with schizophrenia.
•Initiated Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-’2118 in adult participants. NBIP-’2118 is an investigational corticotropin-releasing factor 2 receptor (CRF2) peptide agonist and a potential first-in-class therapy for obesity.
•Presented new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings were presented at the Academy of Managed Care Pharmacy 2026 Annual Meeting in Nashville.
•Presented the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in long-term care settings. The recommendations address persistent gaps in recognizing and managing tardive dyskinesia in this higher-risk population. Findings were presented at the Society for Post-Acute and Long-Term Care Medical Association (PALTmed) PALTC26 Annual Conference in Anaheim, CA.
•Presented new two-year CRENESSITY data demonstrating durable hormonal control, reduced glucocorticoid exposure and meaningful clinical improvements in pediatric patients with classic congenital adrenal hyperplasia. The findings were presented at the Pediatric Endocrine Society 2026 Annual Meeting in San Francisco.
•Promoted Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies.
First-Quarter 2026 Financial Results
| Three Months Ended March 31, | |||||||||||
| (unaudited, in millions, except per share data) | 2026 | 2025 | |||||||||
| Revenues: | |||||||||||
| INGREZZA Net Product Sales | $ | 656.9 | $ | 545.2 | |||||||
| CRENESSITY Net Product Sales | 153.3 | 14.5 | |||||||||
| Other Revenues | 4.3 | 12.9 | |||||||||
| Total Revenues | $ | 814.5 | $ | 572.6 | |||||||
| GAAP Research and Development (R&D) | $ | 296.2 | $ | 263.2 | |||||||
| Non-GAAP R&D | $ | 272.0 | $ | 240.2 | |||||||
| GAAP Selling, General, and Administrative (SG&A) | $ | 318.5 | $ | 276.5 | |||||||
| Non-GAAP SG&A | $ | 281.2 | $ | 245.3 | |||||||
GAAP Operating Income | $ | 193.4 | $ | 23.6 | |||||||
Non-GAAP Operating Income | $ | 226.4 | $ | 78.8 | |||||||
| GAAP Net Income | $ | 197.9 | $ | 7.9 | |||||||
| GAAP Earnings Per Share – Diluted | $ | 1.91 | $ | 0.08 | |||||||
| Non-GAAP Net Income | $ | 200.5 | $ | 71.5 | |||||||
| Non-GAAP Earnings Per Share – Diluted | $ | 1.94 | $ | 0.70 | |||||||
| (unaudited, in millions) | March 31, 2026 | December 31, 2025 | |||||||||
| Total Cash, Cash Equivalents, and Marketable Securities | $ | 2,647.2 | $ | 2,543.4 | |||||||
•Differences in first-quarter 2026 GAAP and Non-GAAP operating expenses compared with first-quarter 2025 were driven by:
◦Increased R&D expense in support of an expanded and advancing pre-clinical and clinical portfolio including investments in osavampator Phase 3 program in major depressive disorder (MDD) and muscarinic franchise, including the direclidine Phase 3 program as a potential treatment for adults with schizophrenia. Development milestone expense included in R&D was $22.6 million and $45.4 million for the first quarter 2026 and 2025.
◦Increased SG&A expense primarily reflected continued investment in our commercial organization, including the expansion of our INGREZZA and CRENESSITY sales teams in the first quarter of 2026.
◦Increased acquired in-process research and development (IPR&D) expense associated with upfront payments for early-stage development candidates license agreements
•First-quarter 2026 GAAP net income and earnings per share were $197.9 million and $1.91, respectively, compared with $7.9 million and $0.08, respectively, for first-quarter 2025.
•First-quarter 2026 Non-GAAP net income and earnings per share were $200.5 million and $1.94, respectively, compared with $71.5 million and $0.70, respectively, for first-quarter 2025.
•Differences in first-quarter 2026 GAAP and Non-GAAP net income compared with first-quarter 2025 were primarily driven by:
◦Higher net product sales of $247.3 million
◦Increased operating expenses in support of expanding and advancing R&D portfolio, continued investment in our commercial organization, including the expansion of our INGREZZA and CRENESSITY sales teams.
◦First quarter 2026 includes:
▪$21.2 million of IPR&D expense associated with upfront payments for early-stage development candidates license agreements
▪$22.6 million of development milestone included in R&D expense, compared with $45.4 million for first quarter 2025
▪A $25.3 million gain from changes in fair values of equity investments compared with a $30.6 million loss for first quarter 2025 (Non-GAAP adjustment)
▪A $28.6 million pre-tax gain, net of transaction costs, related to the sale of Neurocrine Group Limited in January 2026 (Non-GAAP adjustment)
•At March 31, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $2.65 billion.
A reconciliation of GAAP to Non-GAAP financial results can be found in Table 3 and Table 4 at the end of this news release.
Reaffirmed Full-Year 2026 Financial Guidance
| Range | |||||||||||
| (in millions) | Low | High | |||||||||
INGREZZA Net Product Sales 1 | $ | 2,700 | $ | 2,800 | |||||||
GAAP R&D Expense 2 | $ | 1,200 | $ | 1,250 | |||||||
Non-GAAP R&D Expense 2, 3 | $ | 1,110 | $ | 1,160 | |||||||
GAAP and Non-GAAP IPR&D 4 | $ | 20 | $ | 20 | |||||||
GAAP SG&A Expense 5 | $ | 1,375 | $ | 1,400 | |||||||
Non-GAAP SG&A Expense 3, 5 | $ | 1,240 | $ | 1,265 | |||||||
Full-Year 2026 financial guidance excludes any post-close expenses from the announced acquisition of Soleno Therapeutics, anticipated to close in Q2 2026.
1.INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington’s disease.
2.R&D guidance reflects the continued advancement of the Company’s pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in MDD and direclidine in schizophrenia, and includes approximately $25 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve.
3.Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of approximately $90 million in R&D and $125 million in SG&A, divestiture-related expenses and vacated legacy campus facility costs. Non-cash stock-based compensation expense for performance-based equity awards is included in guidance once the predefined performance-based criteria for vesting is achieved or deemed probable to achieve.
4.IPR&D guidance represents completed collaboration and licensing arrangements.
5.SG&A guidance range reflects expense for ongoing commercial initiatives supporting INGREZZA growth and the launch of CRENESSITY including expansion of sales teams.
Conference Call and Webcast Today at 4:30 PM Eastern Time
Neurocrine Biosciences will hold a live conference call and webcast today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Participants can access the live conference call by dialing 800-274-8461 (US) or 203-518-9814 (International) using the conference ID: NBIX. The webcast and accompanying slides can also be accessed at approximately 4:30 p.m. Eastern Time on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neuropsychiatric, neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc.
Non-GAAP Financial Measures
In addition to the financial results and financial guidance that are provided in accordance with accounting principles generally accepted in the United States (GAAP), this press release also contains the following Non-GAAP financial measures: Non-GAAP R&D expense, Non-GAAP SG&A expense, Non-GAAP operating income, Non-GAAP net income and net income per share. When preparing the Non-GAAP financial results and guidance, the Company excludes certain GAAP items that management does not consider to be normal, including recurring cash operating expenses that might not meet the definition of unusual or non-recurring items. In particular, these Non-GAAP financial measures exclude: non-cash stock-based compensation expense, vacated legacy campus facility costs, net of sublease income, non-cash amortization expense related to acquired intangible assets, changes in fair value of equity investments, transaction and divestiture-related gains and/or expenses, changes in foreign currency exchange rates and certain adjustments to income tax expense. These Non-GAAP financial measures are provided as a complement to results provided in accordance with GAAP as management believes these Non-GAAP financial measures help indicate underlying trends in the Company's business, are important in comparing current results with prior period results and provide additional information regarding the Company's financial position. Management also uses these Non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally and to manage the Company's business and evaluate its performance. The Company provides guidance regarding combined R&D and SG&A expenses on both a GAAP and a Non-GAAP basis. A reconciliation of these GAAP financial results to Non-GAAP financial results is included in the attached financial information.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully launching and commercializing CRENESSITY; our financial and operating performance, including our future revenues, expenses, or profits; our plans to acquire Soleno Therapeutics, including the anticipated timing and prospective benefits of the proposed acquisition, and our strategy, plans, objectives, expectations (financial or otherwise) and intentions with respect to our future financial results, growth potential and anticipated product portfolio in connection with the proposed acquisition; our collaborative partnerships; clinical and scientific data updates for our products and product candidates, including observations regarding clinical outcomes, safety, and tolerability; expected future clinical and regulatory milestones; and the timing of the initiation and/or completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements, include but are not limited to the following: risks and uncertainties associated with Neurocrine Biosciences’ business and finances in general; risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to our ability to complete the proposed acquisition of Soleno Therapeutics on the proposed terms or on the proposed timeline, the possibility that competing offers or acquisition proposals will be made, the possibility that the transaction does not close, our ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that we will not be able to integrate Soleno Therapeutics’ business successfully or that such integration may be more difficult, time-consuming or costly than expected, and the degree and pace of market uptake of Soleno Therapeutics’ commercial product, VYKATTM XR (diazoxide choline); risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; risks associated with our ability to manage the growth of our organization; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than as required by law.
###
Contact: Neurocrine Biosciences, Inc.
Tony Jewell (Media)
858-617-7578
media@neurocrine.com
media@neurocrine.com
Todd Tushla (Investors)
858-617-7143
ir@neurocrine.com
TABLE 1
NEUROCRINE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
| Three Months Ended March 31, | |||||||||||
| (in millions, except per share data) | 2026 | 2025 | |||||||||
| Revenues: | |||||||||||
| Net product sales | $ | 811.0 | $ | 563.7 | |||||||
| Collaboration revenues | 3.5 | 8.9 | |||||||||
| Total revenues | 814.5 | 572.6 | |||||||||
| Operating expenses: | |||||||||||
| Cost of revenues | 13.8 | 9.2 | |||||||||
| Research and development | 296.2 | 263.2 | |||||||||
| Acquired in-process research and development | 21.2 | 0.1 | |||||||||
| Selling, general, and administrative | 318.5 | 276.5 | |||||||||
Gain on sale of business, net of transaction costs | (28.6) | — | |||||||||
| Total operating expenses | 621.1 | 549.0 | |||||||||
| Operating income | 193.4 | 23.6 | |||||||||
| Other income (expense): | |||||||||||
| Unrealized gain (loss) on equity investments | 25.3 | (30.6) | |||||||||
| Investment income and other, net | 28.1 | 21.7 | |||||||||
| Total other income (expense), net | 53.4 | (8.9) | |||||||||
| Income before provision for income taxes | 246.8 | 14.7 | |||||||||
| Provision for income taxes | 48.9 | 6.8 | |||||||||
| Net income | $ | 197.9 | $ | 7.9 | |||||||
| Earnings per share, basic | $ | 1.97 | $ | 0.08 | |||||||
| Earnings per share, diluted | $ | 1.91 | $ | 0.08 | |||||||
| Weighted average common shares outstanding, basic | 100.5 | 99.7 | |||||||||
| Weighted average common shares outstanding, diluted | 103.4 | 102.5 | |||||||||
TABLE 2
NEUROCRINE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
| (in millions) | March 31, 2026 | December 31, 2025 | |||||||||
| Cash, cash equivalents, and marketable securities | $ | 1,316.2 | $ | 1,480.4 | |||||||
| Other current assets | 1,119.9 | 1,042.3 | |||||||||
| Total current assets | 2,436.1 | 2,522.7 | |||||||||
| Deferred tax assets | 381.4 | 320.3 | |||||||||
| Marketable securities | 1,331.0 | 1,063.0 | |||||||||
| Right-of-use assets | 447.1 | 455.4 | |||||||||
| Equity investments | 146.1 | 120.8 | |||||||||
| Property and equipment, net | 90.9 | 89.8 | |||||||||
| Other noncurrent assets | 73.6 | 59.5 | |||||||||
| Total assets | $ | 4,906.2 | $ | 4,631.5 | |||||||
| Current liabilities | $ | 831.7 | $ | 743.4 | |||||||
| Noncurrent operating lease liabilities | 406.2 | 415.3 | |||||||||
| Other noncurrent liabilities | 260.9 | 219.7 | |||||||||
| Stockholders’ equity | 3,407.4 | 3,253.1 | |||||||||
| Total liabilities and stockholders’ equity | $ | 4,906.2 | $ | 4,631.5 | |||||||
TABLE 3
NEUROCRINE BIOSCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS
(unaudited)
| Three Months Ended March 31, | |||||||||||
(in millions) | 2026 | 2025 | |||||||||
GAAP operating income 1 | $ | 193.4 | $ | 23.6 | |||||||
| Adjustments: | |||||||||||
| Stock-based compensation expense - R&D | 24.2 | 23.0 | |||||||||
| Stock-based compensation expense - SG&A | 33.0 | 29.8 | |||||||||
Gain on sale of business, net of transaction costs 2 | (28.6) | — | |||||||||
| Amortization of acquired intangible assets | 0.1 | 1.0 | |||||||||
Other 3 | 4.3 | 1.4 | |||||||||
Non-GAAP operating income 1 | $ | 226.4 | $ | 78.8 | |||||||
| Three Months Ended March 31, | |||||||||||
| (in millions, except per share data) | 2026 | 2025 | |||||||||
GAAP net income 1 | $ | 197.9 | $ | 7.9 | |||||||
| Adjustments: | |||||||||||
| Stock-based compensation expense - R&D | 24.2 | 23.0 | |||||||||
| Stock-based compensation expense - SG&A | 33.0 | 29.8 | |||||||||
| Amortization of acquired intangible assets | 0.1 | 1.0 | |||||||||
Changes in fair values of equity investments 4 | (25.3) | 30.6 | |||||||||
Gain on sale of business, net of transaction costs 2 | (28.6) | — | |||||||||
Other 3 | 4.3 | 1.4 | |||||||||
Income tax effect related to reconciling items 5 | (5.1) | (22.2) | |||||||||
Non-GAAP net income 1 | $ | 200.5 | $ | 71.5 | |||||||
| Diluted earnings per share: | |||||||||||
| GAAP | $ | 1.91 | $ | 0.08 | |||||||
| Non-GAAP | $ | 1.94 | $ | 0.70 | |||||||
1. Includes the following expenses:
| Three Months Ended March 31, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Milestones (R&D) | $ | 22.6 | $ | 45.4 | |||||||
| Acquired in-process research and development (IPR&D) | $ | 21.2 | $ | 0.1 | |||||||
2. Reflects a pre-tax gain, net of transaction costs, recognized on the sale of Neurocrine Group Limited in January 2026.
3. Primarily reflects transaction and divestiture-related expenses and other costs associated with our vacated legacy campus facilities, net of sublease income.
4. Reflects periodic fluctuations in the fair values of equity investments.
5. Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance. In addition, Non-GAAP tax expense may also be effected by certain non-recurring, non-operating, or discrete tax items.
TABLE 4
NEUROCRINE BIOSCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP EXPENSES
(unaudited)
| Three Months Ended March 31, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| GAAP cost of revenues | $ | 13.8 | $ | 9.2 | |||||||
| Adjustments: | |||||||||||
| Amortization of acquired intangible assets | 0.1 | 1.0 | |||||||||
| Non-GAAP cost of revenues | $ | 13.7 | $ | 8.2 | |||||||
| Three Months Ended March 31, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| GAAP R&D | $ | 296.2 | $ | 263.2 | |||||||
| Adjustments: | |||||||||||
| Stock-based compensation expense | 24.2 | 23.0 | |||||||||
| Non-GAAP R&D | $ | 272.0 | $ | 240.2 | |||||||
| Three Months Ended March 31, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| GAAP SG&A | $ | 318.5 | $ | 276.5 | |||||||
| Adjustments: | |||||||||||
| Stock-based compensation expense | 33.0 | 29.8 | |||||||||
| Other | 4.3 | 1.4 | |||||||||
| Non-GAAP SG&A | $ | 281.2 | $ | 245.3 | |||||||
| Three Months Ended March 31, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| GAAP other income (expense), net | $ | 53.4 | $ | (8.9) | |||||||
| Adjustments: | |||||||||||
| Changes in fair values of equity investments | (25.3) | 30.6 | |||||||||
| Non-GAAP other income, net | $ | 28.1 | $ | 21.7 | |||||||
FAQ
How did Neurocrine Biosciences (NBIX) perform financially in Q1 2026?
Neurocrine reported Q1 2026 revenues of $814.5 million, up 42% year-over-year, driven by neurology and endocrine products. Net product sales were $811.0 million, while GAAP net income reached $197.9 million and diluted EPS was $1.91, reflecting a strong profitability increase.
What were INGREZZA and CRENESSITY sales for Neurocrine in Q1 2026?
INGREZZA generated $656.9 million in Q1 2026 net product sales, growing 20% year-over-year. CRENESSITY contributed $153.3 million in net product sales, reflecting strong uptake with approximately 80% reimbursement for dispensed prescriptions during the quarter, supporting overall portfolio expansion.
What is included in Neurocrine Biosciences’ acquisition of Soleno Therapeutics?
Neurocrine entered a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, an equity value of $2.9 billion. The deal adds VYKAT XR (diazoxide choline), a first-in-class therapy for hyperphagia in Prader-Willi syndrome, and is expected to close in Q2 2026.
What 2026 guidance did Neurocrine Biosciences reaffirm for INGREZZA?
Neurocrine reaffirmed full-year 2026 INGREZZA net product sales guidance of $2.7–$2.8 billion. This outlook reflects expected demand in tardive dyskinesia and chorea associated with Huntington’s disease, supported by ongoing commercial initiatives and expanded sales-force investment during 2026.
How strong is Neurocrine Biosciences’ cash position after Q1 2026?
As of March 31, 2026, Neurocrine held approximately $2.65 billion in cash, cash equivalents, and marketable securities. This sizable balance provides financial flexibility to fund R&D programs, commercial expansion, and the pending $2.9 billion acquisition of Soleno Therapeutics.
What major R&D and clinical developments did Neurocrine report alongside Q1 2026 results?
Neurocrine initiated a Phase 2 study of NBI-1117570, a dual M1/M4 selective agonist in schizophrenia, and a Phase 1 trial of NBIP-’2118 for obesity. It also presented new INGREZZA, CRENESSITY, and tardive dyskinesia data at multiple medical meetings, supporting its clinical and scientific strategy.